Magnetically active pNIPAM nanosystems as temperature-sensitive biocompatible structures for controlled drug delivery
Metadatos
Afficher la notice complèteAuteur
García Pinel, Beatriz; Cabeza, Laura; Ortiz, Raúl; Prados Salazar, José Carlos; Melguizo Alonso, ConsolaciónEditorial
Taylor y Francis LTD
Materia
PNIPAm Nanosystems Magnetic nanoparticle Fluorouracil; oxaliplatin Colon cancer External magnetic field
Date
2020-01-01Referencia bibliográfica
Garcia-Pinel, B., Ortega-Rodríguez, A., Porras-Alcalá, C., Cabeza, L., Contreras-Cáceres, R., Ortiz, R., ... & López-Romero, J. M. (2020). Magnetically active pNIPAM nanosystems as temperature-sensitive biocompatible structures for controlled drug delivery. Artificial Cells, Nanomedicine, and Biotechnology, 48(1), 1022-1035. [https://doi.org/10.1080/21691401.2020.1773488]
Patrocinador
MINECO CTQ16-76311; Atraccion de Talento fellowship from the Comunidad de Madrid 2018-T1/IND-10736; Junta de Andalucía PI-0476-2016 PI-0102-2017; Instituto de Salud Carlos III PI19/01478; Ministerio de Educación, Ciencia y Deporte y Competitividad (Spain) FPU16_01716Résumé
Here, temperature-sensitive hybrid poly(N-isopropylacrylamide) (pNIPAM) nanosystems with magnetic
response are synthesised and investigated for controlled release of 5-fluorouracil (5FU) and oxaliplatin
(OXA). Initially, magnetic nanoparticles (@Fe3O4) are synthesised by co-precipitation approach and functionalised
with acrylic acid (AA), 3-butenoic acid (3BA) or allylamine (AL) as comonomers. The thermoresponsive
polymer is grown by free radical polymerisation using N-isopropylacrylamide (NIPAM) as
monomer, N,N’-methylenbisacrylamide (BIS) as cross-linker, and 2,2’-azobis(2-methylpropionamidene)
(V50) as initiator. We evaluate particle morphology by transmission electron microscopy (TEM) and particle
size and surface charge by dynamic light scattering (DLS) and Z-potential (ZP) measurements.
These magnetically active pNIPAM@ nanoformulations are loaded with 5-fluorouracil (5FU) and oxaliplatin
(OXA) to determine loading efficiency, drug content and release as well as the cytotoxicity
against T-84 colon cancer cells. Our results show high biocompatibility of pNIPAM nanoformulations
using human blood cells and cultured cells. Interestingly, the pNIPAM@Fe3O4-3BA þ 5FU nanoformulation
significantly reduces the growth of T-84 cells (57% relative inhibition of proliferation). Indeed,
pNIPAM-co-AL@Fe3O4-AA nanosystems produce a slight migration of HCT15 cells in suspension in the
presence of an external magnetic field. Therefore, the obtained hybrid nanoparticles can be applied as
a promising biocompatible nanoplatform for the delivery of 5FU and OXA in the improvement of colon
cancer treatments.